Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

dynavax.com

Founded Year

1996

Stage

IPO | IPO

Total Raised

$80.68M

Date of IPO

2/19/2004

Market Cap

1.30B

Stock Price

10.24

About Dynavax Technologies Corporation

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

Dynavax Technologies Corporation Headquarters Location

2929 Seventh Street Suite 100

Berkeley, California, 94710,

United States

510-848-5100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Dynavax Technologies Corporation

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Dynavax Technologies Corporation is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Dynavax Technologies Corporation Patents

Dynavax Technologies Corporation has filed 58 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/9/2017

6/28/2022

Clusters of differentiation, Autoimmune diseases, Immunology, Immune system, Transcription factors

Grant

Application Date

11/9/2017

Grant Date

6/28/2022

Title

Related Topics

Clusters of differentiation, Autoimmune diseases, Immunology, Immune system, Transcription factors

Status

Grant

Latest Dynavax Technologies Corporation News

Europe Travel Vaccines Market Analysis/Forecast Report 2021-2022 & 2028 Featuring Abbott, Dynavax Technologies, Emergent BioSolutions, GlaxoSmithKline, Merck, Novartis, Pfizer, Sanofi, & Valneva - ResearchAndMarkets.com

Sep 20, 2022

The travel vaccines market in Europe is expected to grow from US$ 995.47 million in 2021 to US$ 1,885.56 million by 2028; it is estimated to grow at a CAGR of 9.6% from 2021 to 2028. Hepatitis, HIV/AIDS, human papillomavirus (HPV), meningococcal disease, typhoid, and yellow fever are among the various chronic diseases detected across the region. Similarly, in 2021, the Centers for Disease Control and Prevention (CDC) launched the global immunization strategic framework 2021-2030. The framework provides a plan to vaccinate against vaccine-preventable diseases (VPDs), such as hepatitis A and B. Moreover, there are different vaccine routines for travelers proposed by WHO to prevent the spread of deadly infectious diseases. The vaccine routine includes routine vaccines for review before traveling, vaccines for certain destinations, and vaccines demanded by certain countries. In most cases, booster doses of routine vaccines are required if people have not followed the regular schedule. Such initiatives by WHO and CDC enhance the vaccine demand, thereby driving its market growth. On the other hand, the COVID-19 outbreak threatened public health. Various emergency actions were initiated during the pandemic, of which the COVAX initiative was aggressively enacted. Vaccination against COVID-19 was mandatory for people worldwide. Governments in every region mandated vaccines for people traveling within and outside countries. The COVID-19 pandemic contributed significantly to travel vaccines. With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe travel vaccines market . Europe Travel Vaccines Market Segmentation In 2021, the others segment held the largest share of the market. In 2021, the outbound travel segment held the largest share of the market. Key Market Dynamics

Dynavax Technologies Corporation Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Dynavax Technologies Corporation Rank

  • When was Dynavax Technologies Corporation founded?

    Dynavax Technologies Corporation was founded in 1996.

  • Where is Dynavax Technologies Corporation's headquarters?

    Dynavax Technologies Corporation's headquarters is located at 2929 Seventh Street, Berkeley.

  • What is Dynavax Technologies Corporation's latest funding round?

    Dynavax Technologies Corporation's latest funding round is IPO.

  • How much did Dynavax Technologies Corporation raise?

    Dynavax Technologies Corporation raised a total of $80.68M.

  • Who are the investors of Dynavax Technologies Corporation?

    Investors of Dynavax Technologies Corporation include InterWest Partners, Axiom Venture Partners, Sanderling Ventures, Alta Partners, Forward Ventures and 15 more.

  • Who are Dynavax Technologies Corporation's competitors?

    Competitors of Dynavax Technologies Corporation include Titan Pharmaceuticals, Apitope, Advaxis, Alethia BioTherapeutics, CureTech, BioMarck Pharmaceuticals, ProCertus BioPharm, Alios BioPharma, Jennerex Biotherapeutics, Circassia Holdings and 21 more.

You May Also Like

XOMA Logo
XOMA

XOMA (NASDAQ: XOMA) is a biotechnology company focused on the discovery and development of monoclonal antibody-based therapeutics. The Company is a late-stage biotechnology company with a diverse portfolio of innovative therapeutic antibodies. XOMA's product candidates are the result of developing monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.

N
Nabi Biopharmaceuticals

has a broad product portfolio that modulates the immune system. Their research focuses on developing and commercializing novel vaccines and antibody-based therapies that prevent and treat infectious, autoimmune and addictive diseases, such as Staphylococcus aureus and hepatitis infections, and nicotine addiction.

S
Spaltudaq

Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

T
Targeted Cell Therapies

Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.

E
Emiliem

Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.